Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

BIOA

BioAge Labs Inc

Last Close
5.87
Nov 11 • 3:59 PM ET Dollar change+0.09 Percentage change(1.56%)
Aftermarket Close
5.58
Aftermarket • 5:44 PM ET Dollar change-0.29 Percentage change(-4.94%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD
Peers: ALT GPCR EYPT KOD NAMS MLYS OCUL CRBP VKTX NVO
 | Held by: VTI IWM VXF XPH IWN IBB VTWO DFAS FESM SCHA
Scroll to Statements
Index
RUT
Market Cap
269.78M
Enterprise Value
-11.13M
Income
-107.80M
Sales
8.60M
Book/sh
7.54
Cash/sh
6.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
62
IPO
Sep 26, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
31.37
P/B
0.78
P/C
0.95
P/FCF
-
EV/EBITDA
-
EV/Sales
-1.29
Quick Ratio
15.51
Current Ratio
15.51
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-2.55
EPS next Y
-2.57
EPS next Q
-0.74
EPS this Y
-16.52%
EPS next Y
1.46%
EPS next 5Y
-4.97%
EPS past 3/5Y
-24.49% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-20.81%
Sales Y/Y TTM
45.33%
EPS Q/Q
-29.72%
Sales Q/Q
-85.49%
Earnings
Nov 05 AMC
EPS/Sales Surpr.
-15.01% -79.83%
Insider Own
31.58%
Insider Trans
-0.43%
Inst Own
61.26%
Inst Trans
11.40%
ROA
-32.05%
ROE
-34.56%
ROIC
-30.94%
Gross Margin
96.72%
Oper. Margin
-1401.81%
Profit Margin
-1253.60%
SMA20
5.75%
SMA50
-13.17%
SMA200
-61.51%
Trades
Shs Outstand
45.95M
Shs Float
31.44M
Short Float
11.85%
Short Ratio
5.05
Short Interest
3.73M
52W High
25.95 -77.38%
52W Low
4.81 22.04%
Volatility
8.74% 7.94%
ATR (14)
0.45
RSI (14)
46.87
Beta
1.19
Rel Volume
0.59
Avg Volume
737.94K
Volume
435,027
Perf Week
-1.34%
Perf Month
5.39%
Perf Quarter
-43.72%
Perf Half Y
-69.33%
Perf YTD
-55.63%
Perf Year
-25.03%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
1.60
Target Price
28.56
Prev Close
5.78
Price
5.87
Change %
1.56%
Consensus
Buy
Avg. Price Target
$28.56
Implied Upside
+386.5%
Analysts10incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 12, 2026Initiated
UBS logoUUBS
Neutral$8+36.3%
May 27, 2026Initiated
RRoth Capital
Buy$36+513.3%
May 13, 2026Initiated
BBTIG Research
Buy$40+581.4%
Mar 27, 2026Initiated
NNeedham
Buy$50+751.8%
Feb 25, 2026Initiated
OPY logoOOppenheimer
Outperform$60+922.1%
Feb 18, 2026Upgrade
JEF logoJJefferies
Hold → Buy$62+956.2%
Jan 27, 2026Initiated
PPiper Sandler
Overweight$73+1,143.6%
Dec 05, 2025Upgrade
MS logoMMorgan Stanley
Underweight → Equal-Weight$12+104.4%
Oct 22, 2025Upgrade
C logoCCitigroup
Neutral → Buy$10+70.4%
Feb 28, 2025Initiated
WWilliam Blair
Mkt Perform
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barton ShanePrincipal Accounting OfficerJun 29 '26Option Exercise6.6139,718262,54242,350Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Option Exercise6.5320,216132,01720,216Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 29 '26Sale25.2142,3501,067,5760Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Sale25.1920,216509,1760Jul 01 04:27 PM
Barton ShaneOfficerJun 30 '26Proposed Sale25.1920,216509,177Jun 30 04:21 PM
Barton ShaneOfficerJun 29 '26Proposed Sale25.2142,3501,067,578Jun 29 04:35 PM
GOLDSTEIN DOV A MDChief Financial OfficerApr 23 '26Option Exercise4.383,54215,51436,575Apr 24 04:19 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Option Exercise5.058,82044,5728,820Apr 03 04:07 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Sale17.818,820157,0840Apr 03 04:07 PM
RUBIN PAUL DOfficerApr 01 '26Proposed Sale17.818,820157,084Apr 01 10:53 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.777,43335,4707,433Mar 03 04:46 PM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 04:46 PM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.383,54215,51433,033Mar 03 04:44 PM
RUBIN PAUL DOfficerMar 02 '26Proposed Sale20.037,433148,883Mar 02 10:17 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Option Exercise4.777,43335,4707,433Feb 03 04:26 PM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Sale18.757,433139,3690Feb 03 04:26 PM
GOLDSTEIN DOV A MDChief Financial OfficerFeb 01 '26Option Exercise4.383,54115,51029,491Feb 03 04:23 PM
RUBIN PAUL DOfficerFeb 02 '26Proposed Sale18.757,433139,369Feb 02 09:43 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 16 '26Option Exercise4.383,54215,51425,950Jan 21 04:20 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Option Exercise8.3927,000226,53049,408Jan 15 04:22 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Sale19.7027,000531,82822,408Jan 15 04:22 PM
Fortney KristenChief Executive OfficerJan 13 '26Sale18.12233,1074,223,036976,949Jan 15 04:20 PM
Fortney Kristen10% OwnerJan 13 '26Proposed Sale18.00233,1074,195,926Jan 13 04:36 PM
GOLDSTEIN DOV A MDOfficerJan 13 '26Proposed Sale19.7027,000531,828Jan 13 04:16 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Option Exercise4.777,43335,4707,433Jan 06 04:24 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Sale12.857,43395,4900Jan 06 04:24 PM
RUBIN PAUL DOfficerJan 02 '26Proposed Sale13.417,43399,677Jan 02 12:56 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Option Exercise6.5718,000118,26018,000Dec 11 04:21 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Sale12.0018,000216,0000Dec 11 04:21 PM
RUBIN PAUL DOfficerDec 09 '25Proposed Sale12.0018,000216,000Dec 09 11:23 AM
RUBIN PAUL DChief Medical OfficerDec 04 '25Option Exercise4.1168,897283,16768,897Dec 05 06:20 PM
RUBIN PAUL DChief Medical OfficerDec 04 '25Sale10.1968,897701,9090Dec 05 06:20 PM
RUBIN PAUL DOfficerDec 04 '25Proposed Sale10.1968,897701,912Dec 04 04:30 PM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Co-FounderDr. Kristen Fortney Ph.D.
Co-FounderDr. Eric Morgen M.D.
Chief Medical Officer & Executive VP of ResearchDr. Paul D. Rubin M.D.
M.D.Dr. Dov A. Goldstein M.B.A.
Senior Vice President of Finance & AccountingMr. Shane Barton CPA
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)